Viewing Study NCT04736706

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 4:00 PM
Ignite Modification Date: 2026-01-13 @ 5:36 AM
Study NCT ID: NCT04736706
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-11-18
First Post: 2021-01-29
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Sponsor: Merck Sharp & Dohme LLC
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Carcinoma, Renal Cell View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Programmed Cell Death-1 (PD1, PD-1) View
None Programmed Death-Ligand 1 (PDL1, PD-L1) View
None Hypoxia inducible factor (HIF) View
None Hypoxia inducible factor 1B (HIF-1B) View
None Hypoxia inducible factor 2 alpha (HIF-2 alpha) View